Drug Profile
Research programme: bacteriophage-based antibacterial therapeutics - Armata Pharmaceuticals/Westmead Institute for Medical Research
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator AmpliPhi Biosciences Corporation; Westmead Institute for Medical Research
- Developer Armata Pharmaceuticals; Westmead Institute for Medical Research
- Class Bacteriophages
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Bacterial-infections in Australia
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 09 Feb 2016 Early research in Bacterial infections in Australia (unspecified route)